#154840

Anti-Von Willebrand Factor [F8/44/20] rAb

Cat. #154840

Anti-Von Willebrand Factor [F8/44/20] rAb

Cat. #: 154840

Unit size: 100 ug

Availability: 10-12 weeks

Target: Von Willebrand factor (VWF)

Class: Recombinant

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Absolute Antibody ; University of Oxford

Tool Details
Target Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Von Willebrand Factor [F8/44/20] rAb
  • Clone: F8/44/20
  • Class: Recombinant
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Description: Von Willebrand factor (vWF) mediates platelet adhesion to injured endothelium, the first step in hemostasis, and helps maintain factor VIII levels. When vWF is deficient, patients have a bleeding disorder called von Willebrand disease (vWD).
  • Immunogen: Von Willebrand factor isolated from human plasma
  • Isotype: IgG1

Target Details

  • Target: Von Willebrand factor (VWF)
  • Target background: Von Willebrand factor (vWF) mediates platelet adhesion to injured endothelium, the first step in hemostasis, and helps maintain factor VIII levels. When vWF is deficient, patients have a bleeding disorder called von Willebrand disease (vWD).

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C

References

  • Description of a sequential staining procedure for double immunoenzymatic staining of pairs of antigens using monoclonal antibodies.
  • Falini et al. 1984. Br J Haematol. 56(3):365-86. PMID: 6365152.
  • Falini et al. 1986. J Immunol Methods. 93(2):265-73. PMID: 2430024.
  • Immunohistological analysis of human bone marrow trephine biopsies using monoclonal antibodies.
  • Naiem et al. 1982. J Immunol Methods. 50(2):145-60. PMID: 6806388.
  • The value of immunohistological screening in the production of monoclonal antibodies.